bisoprolol and Death, Sudden, Cardiac studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)

Research Excerpts

Excerpt	Relevance	Reference
"Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain."	6.71	Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003)
"Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4."	3.72	[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004)
"The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown."	2.74	Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). ( Abbate, A; Erne, P; Jamshidi, P; Kobza, R; Pfisterer, M; Schoenenberger, AW; Stuck, AE; Zuber, M, 2009)
"Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain."	2.71	Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003)
"The heart failure is one of the pathologies with major social and economic impact in the western world."	2.44	[Chronic heart failure and sudden death: the message of CIBIS-III]. ( Dequarti, MC; Poggio, L; Vanoli, E, 2007)

Research

Studies (14)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Change From Baseline in BNP Levels

Change From Baseline in Deceleration Time

Change From Baseline in Early to Late Atrial Ratio (E:A Ratio)

Change From Baseline in End Diastolic Dimension (EDD)

Change From Baseline in End Systolic Dimension (ESD)

Change From Baseline in Intraventricular Septal Thickness (IVST)

Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV)

Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)

Change From Baseline in Left Ventricular End Systolic Volume (LVESV)

Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (21.43)	18.2507
2000's	8 (57.14)	29.6817
2010's	1 (7.14)	24.3611
2020's	2 (14.29)	2.80

Authors	Studies
Sánez Tähtisalo, H	1
Hiltunen, TP	1
Kenttä, T	1
Junttila, J	1
Oikarinen, L	1
Virolainen, J	1
Kontula, KK	1
Porthan, K	1
Sirico, G	1
Montisci, A	1
Secchi, F	1
Mantica, M	1
Schoenenberger, AW	2
Kobza, R	1
Jamshidi, P	1
Zuber, M	2
Abbate, A	1
Stuck, AE	1
Pfisterer, M	2
Erne, P	2
Krum, H	1
van Veldhuisen, DJ	1
Funck-Brentano, C	2
Vanoli, E	2
Silke, B	1
Erdmann, E	1
Follath, F	1
Ponikowski, P	1
Goulder, M	1
Meyer, W	1
Lechat, P	2
Willenheimer, R	1
Simon, T	1
Mary-Krause, M	1
Jaillon, P	1
Kanopskiĭ, SG	1
Staritskiĭ, AG	1
Bozhko, AA	1
Kowey, PR	1
Burckhardt, D	1
Kiowski, W	1
Dubach, P	1
Resink, T	1
Dequarti, MC	1
Poggio, L	1
Drummond, GA	1
Squire, IB	1
Kendall, MJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.[NCT01870310]		50 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446]		81 participants (Anticipated)	Observational [Patient Registry]	2017-11-02	Recruiting
A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037]	Phase 3	318 participants (Actual)	Interventional	2006-03-31	Completed
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442]		18,240 participants (Anticipated)	Observational	2008-08-31	Enrolling by invitation
The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612]		7,057 participants (Actual)	Observational [Patient Registry]	2009-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.88
Carvedilol Controlled Release	-0.86

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	24.00
Carvedilol Controlled Release	53.37

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.20
Carvedilol Controlled Release	-0.45

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.33
Carvedilol Controlled Release	-0.36

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-0.76
Carvedilol Controlled Release	-0.83

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	.08
Carvedilol Controlled Release	.05

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	.08
Carvedilol Controlled Release	.08

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-36.61
Carvedilol Controlled Release	-42.22

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-18.29
Carvedilol Controlled Release	-20.57

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	-36.61
Carvedilol Controlled Release	-43.00

Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Change From Baseline in Left Ventricular Mass (LVM)

Change From Baseline in Posterior Wall Thickness (PWT)

Safety and Tolerability of Coreg CR

Intervention	mL/m^2 (Mean)
Coreg Immediate Release	-18.36
Coreg Controlled Release	-20.81

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	9.5
Carvedilol Controlled Release	-9.29

Intervention	percentage of change (Mean)
Carvedilol Immediate Release	.07
Carvedilol Controlled Release	.05

SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)

Intervention	subjects in each treatment group (Number)
	Study Entry (10mg Coreg CR, 3.125mg Coreg IR)	Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR)	End of Study (10mg Coreg CR, 3.125mg Coreg IR)	Study Entry (20mg Coreg CR, 6.25mg Coreg IR)	Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR)	End of Study (20mg Coreg CR, 6.25mg Coreg IR)	Study Entry (40mg Coreg CR, 12.5mg Coreg IR)	Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR)	End of Study (40mg Coreg CR, 12.5mg Coreg IR)	Study Entry (80mg Coreg CR, 25mg Coreg IR)	Maintenance Entry (80mg Coreg CR, 25mg Coreg IR)	End of Study (80mg Coreg CR, 25mg Coreg IR)
Carvedilol Controlled Release	83	0	4	39	9	16	27	16	22	4	114	111
Carvedilol Immediate Release	79	0	7	61	13	16	21	12	21	4	116	121

Article	Year
A review of carvedilol arrhythmia data in clinical trials. Journal of cardiovascular pharmacology and therapeutics, 2005, Volume: 10 Suppl 1 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca	2005
[Chronic heart failure and sudden death: the message of CIBIS-III]. Recenti progressi in medicina, 2007, Volume: 98, Issue:12 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents	2007

Article	Year
Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). The American journal of cardiology, 2009, Jul-15, Volume: 104, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Antihypertensi	2009
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. Cardiovascular therapeutics, 2011, Volume: 29, Issue:2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis	2011
Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). European heart journal, 2003, Volume: 24, Issue:6 Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; D	2003
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study. European heart journal, 2007, Volume: 28, Issue:17 Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su	2007
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou	1999

Article	Year
Effect of four classes of antihypertensive drugs on cardiac repolarization heterogeneity: A double-blind rotational study. PloS one, 2020, Volume: 15, Issue:3 Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bisoprolol;	2020
Myotonic dystrophy type 1 and high ventricular vulnerability at the electrophysiological evaluation: ICD yes or not? Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 2020, Volume: 39, Issue:1 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Bisoprolol; Clinical Decision-Making; Death, Sudden,	2020
[Longevity promoting beta blocker. Soon in 1st place in heart failure?]. MMW Fortschritte der Medizin, 2003, Sep-11, Volume: 145, Issue:37 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Cause of Death; C	2003
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. Kardiologiia, 2004, Volume: 44, Issue:10 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti	2004
[Beginning therapy of heart failure with beta blockers. Do these patients survive longer?]. MMW Fortschritte der Medizin, 2005, Sep-29, Volume: 147, Issue:39 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Death, Sudden, Ca	2005
The Cardiac Insufficiency Bisoprolol Study II. Lancet (London, England), 1999, Apr-17, Volume: 353, Issue:9161 Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans	1999
Possible mechanisms of action in the positive effect of beta blockers in heart failure. Heart (British Cardiac Society), 1999, Volume: 82 Suppl 4 Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans; Myocardial I	1999

bisoprolol and Death, Sudden, Cardiac